Benign Prostatic HyperplasiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

1207 records returned

Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sampleEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The inconsistent associations observed herein and for other gene polymorphisms warrant further studies. In general, the data regarding the association of gene polymorphism to BPH-parameters suggest that this disease is caused by multiple rather than a single genetic variant. A rigorous patient selection based on anatomo-pathological and hormonal profile may possible reduce the number of confounders for future studies thus enabling a more detailed assessment of the association between genetic factors and BPH-parameters. Content Type Journal ArticleCategory Topic PaperDOI 10.1007/s00345-009-...
Source: World Journal of Urology - November 18, 2009 Category: Urology & Nephrology Tags: World Journal of Urology Source Type: journals

70 vs 120 W thulium:yttrium-aluminium-garnet 2 µm continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex-vivo evaluationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To evaluate the ablative and haemostatic properties of the recently introduced 120-W thulium:yttrium-aluminium-garnet (Tm-YAG) laser and to assess these results against those of the previously introduced 70-W Tm-YAG laser. The ex-vivo model of the isolated blood-perfused porcine kidney was used to determine the ablation capacity, haemostatic properties and coagulation depth of a 2 µm continuous-wave Tm-YAG laser. The energy was delivered using a 550-µm and an 800-µm bare-ended fibre. The results of the recently introduced 120-W Tm-YAG were compared to the established 70-W device. Kidney tissue was embedded for histologi...
Source: BJU International - November 13, 2009 Category: Urology & Nephrology Authors: Thorsten Bach, Nina Huck, Felix Wezel, Axel Häcker, Andreas J. Gross, Maurice Stephan Michel Source Type: journals

Prostatic Artery Embolization as a Primary Treatment for Benign Prostatic Hyperplasia: Preliminary Results in Two PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the preliminary results for two patients with acute urinary retention due to BPH, successfully treated by prostate artery embolization (PAE). The patients were investigated using the International Prostate Symptom Score, by digital rectal examination, urodynamic testing, prostate biopsy, transrectal ultrasound (US), and magnetic resonance imaging (MRI). Uroflowmetry and postvoid residual urine volume complemented the investigation at 30, 90, and 180 days after PAE. The procedure was performed under local anesthesia; embolization of the prostate arteries was performed with a microcatheter and 300- to 500...
Source: CardioVascular and Interventional Radiology - November 12, 2009 Category: Radiology Tags: CardioVascular and Interventional Radiology Source Type: journals

Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Present study depicted the role of polymorphisms in estrogen receptor-alpha gene in association with prostate cancer in north Indian population. The study was performed on 157 cases of prostate cancer, 170 cases of BPH, and 170 healthy Indian males diagnosed with prostate cancer and benign prostatic hyperplasia (BPH) and healthy males as controls. Determination of polymorphism in the ER-alpha gene was done by polymerase chain reaction followed by restriction fragment length polymorphism (RFLP) analysis with PvuII and XbaI enzymes. An association was observed between PvuII polymorphism of ER-alpha gene and that of prost...
Source: Molecular and Cellular Biochemistry - November 11, 2009 Category: Biochemistry Authors: Gupta L, Thakur H, Sobti RC, Seth A, Singh SK Tags: Mol Cell Biochem Source Type: journals

The Impact of Diabetes Type 2 in the Pathogenesis of Benign Prostatic Hyperplasia: A ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion. Evidence suggests that an association between BPH and diabetes through a common pathogenic mechanism is possible. The specific pathway interfering in the development of both conditions is still poorly investigated; thus, the exact relationship of BPH to diabetes remains unclear. (Source: Advances in Urology)
Source: Advances in Urology - November 9, 2009 Category: Urology & Nephrology Source Type: journals

Primary Care and Urology BPH Management ComparedEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The evaluation and treatment of benign prostatic hyperplasia by primary care physicians is less rigorous than evaluation and treatment by urologists, according to a study in the November issue of The Journal of Urology. (Source: Modern Medicine)
Source: Modern Medicine - November 9, 2009 Category: Journals (General) Source Type: info

Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chronic inflammation is commonly observed in benign prostate hyperplasia (BPH), and prostate tissue often contains increased inflammatory infiltrates, including T cells and macrophages. Cytokines are not only key mediators of inflammation but may also play important roles in the initiation and progression of BPH.In order to determine what cytokines might be involved in prostatic enlargement, expressed prostatic secretions (EPS) from ex vivo prostates were analyzed by human cytokine antibody microarray and ELISA. Prostate epithelial cells (PrEC) and prostate stromal cells (PrSC) were used for ELISA, proliferation, and Weste...
Source: The Prostate - November 9, 2009 Category: Urology & Nephrology Authors: Kazutoshi Fujita, Charles M. Ewing, Robert H. Getzenberg, J. Kellogg Parsons, William B. Isaacs, Christian P. Pavlovich Source Type: journals

An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Based on the analysis of MSHQ scores before and after alfuzosin treatment, improvement was significant on ejaculatory function, in addition to improvement on LUTS and quality of life. MSHQ is a useful tool to evaluate the male sexual dysfunction. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - November 4, 2009 Category: Internal Medicine Authors: M. K. Kim, J. Cheon, K. S. Lee, M.K. Chung, J. Y. Lee, S.W. Lee, S. W. Kim, B. H. Chung, K. Park, J. K. Park Source Type: journals

Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstructionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To evaluate the urodynamic effects of fesoterodine, a new antimuscarinic agent, alone and combined with doxazosin, in a rat model of partial urethral obstruction (PUO), as 35[ndash]83% of men with bladder outlet obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) have overactive bladder (OAB) syndrome, and as the combination of [alpha]1-adrenoceptor- and muscarinic-receptor antagonists has been proposed to be beneficial for these patients. Thirty-seven male Sprague-Dawley rats (250 g) had surgically induced PUO; 2 weeks later they were evaluated by cystometry with no anaesthesia or any restraint. After a 1-h ...
Source: BJU International - November 3, 2009 Category: Urology & Nephrology Authors: Claudius Füllhase, Roberto Soler, Christian Gratzke, Marina Brodsky, George J. Christ, Karl-Erik Andersson Source Type: journals

Extended-Release Doxazosin for Treatment of Renal Transplant Recipients With Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Extended-release doxazosin treatment was effective and safe in renal transplant recipients with BPH. The drug not only had no influence on renal graft function and trough concentrations of immunosuppressant, but improved hypertension in these patients. (Source: Transplantation Proceedings)
Source: Transplantation Proceedings - November 1, 2009 Category: Transplant Surgery Authors: Y. Zhang, Y. Wang, P. Zhang, X.D. Zhang, Y. Yang Tags: Renal Transplantation Source Type: journals

Silodosin and naftopidil both improve QOL in male patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2009 Category: Health Management Tags: Research article Source Type: journals

Icaritin induces growth inhibition and apoptosis of human prostatic smooth muscle cells in an estrogen receptor-independent manner.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Icaritin has selective estrogen receptor (ER) modulating activity. ERs are expressed in the prostate stroma, and estrogens have an important role in the pathology of benign prostatic hyperplasia (BPH). However, the impact of icaritin on BPH was not studied. Human prostatic smooth muscle cells (PSMCs) were treated with 0-100 muM icaritin, also using 10 muM ICI182780 as a specific ER antagonist. The effects on cell growth and apoptosis were determined by cell counting and sandwich-enzyme-immunoassay. Western blotting was employed to illustrate the possible mechanisms. Cell growth was strongly inhibited by icaritin, and t...
Source: Amino Acids - October 30, 2009 Category: Biochemistry Authors: Chen MF, Qi L, Li Y, Zu XB, Dai YQ, Zhang P Tags: Amino Acids Source Type: journals

Leukocytic promotion of prostate cellular proliferationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Histological evidence of pervasive inflammatory infiltrate has been noted in both benign prostatic hyperplasia/hypertrophy (BPH) and prostate cancer (PCa). Cytokines known to attract particular leukocyte subsets are secreted from prostatic stroma consequent to aging and also from malignant prostate epithelium. Therefore, we hypothesized that leukocytes associated with either acute or chronic inflammation attracted to the prostate consequent to aging or tumorigenesis may promote the abnormal cellular proliferation associated with BPH and PCa.An in vitro system designed to mimic the human prostatic microenvironment incorpora...
Source: The Prostate - October 29, 2009 Category: Urology & Nephrology Authors: Kristy L. McDowell, Lesa A. Begley, Nirit Mor-Vaknin, David M. Markovitz, Jill A. Macoska Source Type: journals

Both nongenomic and genomic effects are involved in estradiol's enhancing the phenotype of smooth muscle cells in cultured prostate stromal cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Stromal smooth muscle cells (SMCs) play an important role in the pathogenesis and clinical symptom of benign prostatic hyperplasia. We had reported that estrogen enhances the phenotype of SMC in cultured prostate stromal cells (PRSCs). Here we further investigate the mechanism by which estrogen affects the differentiation of PRSCs.Primary cultured PRSCs were stimulated with E2 or BSA-E2. The mRNA level of SMC-specific genes, smoothelin, and SM-MHC were measured by qRT-PCR. The SM-MHC protein was measured by Western blot. The mRNA and protein levels of TGF-[beta]1 were measured by qRT-PCR and ELISA. The MAPK inhibitor PD980...
Source: The Prostate - October 28, 2009 Category: Urology & Nephrology Authors: Zhisong Zhang, Liang Wang, Mei Mei, Yan Zhu, Xiaoling Du, Chung Lee, Irwin Park, Ju Zhang, Jiandang Shi Source Type: journals

Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To analyse potential association of various clinical characteristics of benign prostatic hyperplasia (BPH) with chronic kidney disease (CKD) among men presenting with lower urinary tract symptoms (LUTS) secondary to BPH of varying severity. We reviewed the data of 2741 consecutive patients who presented to our clinic with LUTS secondary to BPH. For our analysis, CKD was defined by an elevated serum creatinine level or decreased estimated glomerular filtration rate (eGFR). Univariate and multivariate logistic regression analyses were used to address associations of CKD with various clinical characteristics. Of the 2741 pati...
Source: BJU International - October 28, 2009 Category: Urology & Nephrology Authors: Sung Kyu Hong, Seung Tae Lee, Sung Jin Jeong, Seok-Soo Byun, Young Kwon Hong, Dong Soo Park, Jae Yup Hong, Jeong Hwan Son, Cheil Kim, Seok Heun Jang, Sang Eun Lee Source Type: journals

TRPV6 alleles do not influence prostate cancer progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Our results show that the frequencies of trpv6 alleles in healthy control individuals and prostate cancer patients are not significantly different. Although expression of trpv6 transcripts correlates with aggressive potential of prostate cancer, the TRPV6 genotype does not correlate with the onset of prostate cancer, with the Gleason score and the tumour stage. (Source: BMC Cancer)
Source: BMC Cancer - October 26, 2009 Category: Cancer & Oncology Authors: Thorsten KesslerUlrich WissenbachRainer GrobholzVeit Flockerzi Source Type: journals

Development and validation of an Arabic version of the International Prostate Symptom ScoreEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To develop and validate an Arabic version of the International Prostate Symptom Score (IPSS). An Arabic version of the IPSS (IPSS-Arb) was developed through a series of translations and modifications which involved the authors, urology and non-urology medical and nursing staff. The validity and reliability were assessed in 76 patients with urinary symptoms due to benign prostatic hyperplasia (BPH) and in 63 control subjects without BPH; 25 patients had transurethral resection of prostate (TURP) whereas the remaining 51 patients were treated with terazosin. The reliability of the IPSS-Arb was assessed by determining the int...
Source: BJU International - October 26, 2009 Category: Urology & Nephrology Authors: Fayez T. Hammad, Mohammed A. Kaya Source Type: journals

The role of nocturia in the quality of life of men with lower urinary tract symptomsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To determine the role of treatment-associated improvement in nocturia in health-related quality of life (HRQL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia, and secondarily to confirm the role of nocturia in HRQL at baseline and to compare the effects of watchful waiting, transurethral microwave treatment (TUMT) and transurethral resection of the prostate (TURP) to those of [alpha]1-adrenoceptor antagonists ([alpha]-blockers) on nocturia. We retrospectively analysed using multiple regression a large single-centre database of patients receiving routine care for treatment-as...
Source: BJU International - October 26, 2009 Category: Urology & Nephrology Authors: Marleen M. van Dijk, Hessel Wijkstra, Frans M. Debruyne, Jean J.M.C.H. de la Rosette, Martin C. Michel Source Type: journals

[Pharmacological treatment of benign prostatic hyperplasia.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The majority of men with benign prostatic hyperplasia (BPH) seek medical help because of lower urinary tract symptoms (LUTS). Pharmacological treatment of BPH is indicated if the patient has no absolute indications for prostate surgery or benign prostatic obstruction (BPO), but LUTS with a decrease of quality of life. Plant extracts can be prescribed in men with mild to moderate symptoms. alpha-Blockers can quickly and effectively decrease LUTS and symptomatic disease progression. If patients have predominantly bladder filling symptoms and a small prostate, muscarinic receptor antagonists are a viable treatment option....
Source: Der Urologe. Ausg. A - October 23, 2009 Category: Urology & Nephrology Authors: Oelke M, Kuczyk MA, Herrmann TR Tags: Urologe A Source Type: journals

Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Treatment with the combination of tamsulosin only and sildenafil citrate only was not superior to tamsulosin only to enhance voiding symptoms. Also, sexual function improvement was similar for both the combination and sildenafil citrate only treatments. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00345-009-0484-zAuthors Altug Tuncel, Ministry of Health, Ankara Numune Research and Training Hospital Third Department of Urology 06120 Sihhiye, Ankara TurkeyVarol Nalcacioglu, Ministry of Health, Ankara Numune Research and Training Hospital Third Department of Urology 06120 ...
Source: World Journal of Urology - October 23, 2009 Category: Urology & Nephrology Tags: World Journal of Urology Source Type: journals

Charity campaigns for QOF to include prostate enlargementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Charity Prostate UK has given evidence to NICE suggesting benign prostatic hyperplasia (BPH) is included in the quality framework (QOF). (Source: HealthcareRepublic Independent Nurse News)
Source: HealthcareRepublic Independent Nurse News - October 21, 2009 Category: Nursing Source Type: news

Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
R. Muecke, T. Klotz, J. Giedl, J. Buentzel, G. Kundt, K. Kisters, F. J. Prott and O. Micke Department of Radiotherapy, St. Josefs-Hospital, Wiesbaden, Germany (Source: The Journal of Urology)
Source: The Journal of Urology - October 19, 2009 Category: Urology & Nephrology Authors: Steven A. Kaplan Tags: Urological Survey Source Type: journals

Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
K. Zhang, Z. Xu, J. Zhang, H. Wang, D. Zhang and B. Shi Department of Urology, Qilu Hospital of Shandong University, Jinan, China (Source: The Journal of Urology)
Source: The Journal of Urology - October 19, 2009 Category: Urology & Nephrology Authors: Steven A. Kaplan Tags: Urological Survey Source Type: journals

Prostate hyperplasia can be treated by drug combination, says studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Two drugs used to treat benign prostate hyperplasia (BPH) work better in combination than on their own, according to a study by GlaxoSmithKline. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - October 14, 2009 Category: Nursing Source Type: news

Structural changes in α1-adrenoceptor antagonist-treated human prostatic stromaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract α1-Adrenoceptor antagonists (α1-blockers) are currently used as first-line drugs for the treatment of benign prostatic hyperplasia (BPH). However, cases of BPH are often encountered in which the efficacy of α1-blockers decreases and switching to surgical treatment is required. One factor responsible for this resistance includes structural changes in prostatic tissue architecture following repeated oral administration of α1-blockers. Forty patients suspected of having prostate cancer, but without evidence of malignancy on prostatic biopsy were divided into two groups: an untreated group (n =...
Source: Clinical and Experimental Medicine - October 13, 2009 Category: Research Tags: Clinical and Experimental Medicine Source Type: journals

GSK?s Avodart / tamsulosin combination showed benefits for men with prostate enlargementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
MISSISSAUGA, ON (October 13, 2009) The final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia*... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 13, 2009 Category: Pharmaceuticals Source Type: clinical trials

GSK's Avodart® / tamsulosin combination showed benefits for men with prostate enlargementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (GSK) announced that final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia* (BPH)-related surgery and reduced the risk of BPH clinical progression more than tamsulosin alone**. (Source: World Pharma News)
Source: World Pharma News - October 12, 2009 Category: Pharmaceuticals Source Type: news

Transurethral Vapor Resection of Prostate—An Alternative Treatment for Benign Prostatic Hyperplasia >100 gEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Endourology , Vol. 0, No. 0. (Source: Journal of Endourology)
Source: Journal of Endourology - October 12, 2009 Category: Urology & Nephrology Tags: article Source Type: journals

Stone Formation in Prostatic Urethra After Potassium-Titanyl-Phosphate Laser Ablation of the Prostate for Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Endourology , Vol. 0, No. 0. (Source: Journal of Endourology)
Source: Journal of Endourology - October 12, 2009 Category: Urology & Nephrology Tags: article Source Type: journals

Avodart (dutasteride) in combination with tamsulosin shows benefits for men with benign prostatic hyperplasia (enlarged prostate)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LONDON, Oct. 12, 2009--GlaxoSmithKline (GSK) announced today the final results from its 4-year CombAT (Combination therapy with Avodart and Tamsulosin) study, which have been published online in European Urology. The results show that combined... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 12, 2009 Category: Pharmaceuticals Source Type: clinical trials

GSK’s Avodart® / tamsulosin combination showed benefits for men with prostate enlargementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
GlaxoSmithKline (GSK) announced today that final results from a large, 4-year study showed that Avodart (dutasteride) and tamsulosin combination treatment reduced the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia* (BPH)-related surgery and reduced the risk of BPH clinical progression more than tamsulosin alone (Source: GSK news)
Source: GSK news - October 12, 2009 Category: Pharmaceuticals Source Type: organizations

The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline. Fifty-three patients with LUTS (IPSS score > 7) whose maximum flow rate (Q(max)) < 15 mL s(-1) and PSA < 4 ng dL(-1) were enrolled in the study. Patients received doxazosin 4 mg once daily for 6 weeks. Subjective efficacy was assessed by IPSS, IPSS-Quality of Life (IPSS-QoL) for LUTS and efficacy was assessed by International Index of Erectile Function (IIEF) for erectile functions at baseline and sixth weeks. The objective...
Source: Asian Journal of Andrology - October 11, 2009 Category: Urology & Nephrology Authors: Demir O, Ozdemir I, Bozkurt O, Aslan G, Esen AA Tags: Asian J Androl Source Type: journals

β-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To investigate the patterns of expression of the junctional proteins [beta]-catenin and claudins in different prognostic groups of patients with prostatic cancer, to determine their value as prognostic markers. We evaluated the samples of 30 patients who had a radical prostatectomy for organ-confined cancer (pT2N0M0), men with clinically advanced cancer, and a control group with benign prostatic hyperplasia. Using immunohistochemistry applied to tissue microarrays, each group was evaluated for claudin-1, -2, -3, -4, -5, -7, -8 and -10, and [beta]-catenin expression. There were differences among the three groups in the expr...
Source: BJU International - October 9, 2009 Category: Urology & Nephrology Authors: Attila M. Szász, Péter Nyirády, Attila Majoros, Attila Szendrõi, Miklós Szûcs, Eszter Székely, Anna-Mária Tõkés, Imre Romics, Janina Kulka Source Type: journals

Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Our post-treatment data support the idea of a cause–effect relationship between voiding symptoms and QoL irrespective of treatment form. While both voiding and storage symptoms contribute to this relationship, storage symptoms play a somewhat greater role. Content Type Journal ArticleCategory Topic PaperDOI 10.1007/s00345-009-0480-3Authors Petros Sountoulides, Academic Medical Center Department of Urology Amsterdam The NetherlandsMarleen M. van Dijk, Academic Medical Center Department of Urology Amsterdam The NetherlandsHessel Wijkstra, Academic Medical Center Department of Urology Amster...
Source: World Journal of Urology - October 9, 2009 Category: Urology & Nephrology Tags: World Journal of Urology Source Type: journals

Comparison of the thermal and histopathological effects of bipolar and monopolar electrosurgical resection of the prostate in a canine modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To compare the thermal and histopathological effects of two commercially available bipolar systems and conventional monopolar transurethral resection of the prostate (TURP) in a canine model. Bipolar TURP is an alternative to monopolar electrosurgery for treating benign prostatic hyperplasia and has several potential clinical advantages, including the ability to use normal saline irrigation, enhanced haemostasis and less collateral thermal damage. In all, 12 adult male beagles were studied. After midline laparotomy and exposure of the bladder and prostate, two fibre-optic thermosensors were placed to record tissue temperat...
Source: BJU International - October 7, 2009 Category: Urology & Nephrology Authors: Raymond Ko, Andrew H.H. Tan, Ben H. Chew, P. Elaine Rowe, Hassan Razvi Source Type: journals

Impax Laboratories Receives Tentative FDA Approval For Generic FLOMAX(R) 0.4mg CapsulesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. Boehringer Ingelheim Pharmaceuticals, Inc. markets FLOMAX® for the functional symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 7, 2009 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news

The Effect of Dutasteride on the Efficacy of Photoselective Vaporization of the Prostate: Results of a Randomized, Placebo-controlled, Double-blind Study (DOP Trial)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Compared with patients randomized to placebo, patients randomized to dutasteride experienced a trend toward decreased time, joules used, and blood loss during surgery. Although we could not convincingly prove an operative benefit of treatment with dutasteride before surgery, we have demonstrated the efficacy of PV in men receiving dutasteride. (Source: Urology)
Source: Urology - October 5, 2009 Category: Urology & Nephrology Authors: Jennifer L. Bepple, Bethany B. Barone, Gregg Eure Tags: prostatic Diseases and Male Voiding Dysfunction Source Type: journals

AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary EndpointEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUEBEC CITY, Sept. 30 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 4, 2009 Category: Pharmaceuticals Source Type: clinical trials

Challenging non-traumatic posterior urethral strictures treated with urethroplasty: a preliminary reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Posterior non-traumatic strictures refractory to minimal invasive procedures (dilation/endoscopic urethrotomy) can be treated by urethroplasty using an anastomotic repair with a bladder neck incision if necessary. (Source: International Braz J Urol)
Source: International Braz J Urol - October 2, 2009 Category: Urology & Nephrology Source Type: journals

Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing worldEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Varshney Anil, Agarwal AnshumanIndian Journal of Urology 2009 25(3):409-412Lasers have arrived in a big way for the management of benign prostatic hyperplasia. The most common ones in use are holmium, potassium titanyl phosphate (KTP) and thulium.They remove the prostatic adenoma either by way of enucleation or ablation. Backed by numerous studies that prove their safety, efficacy and durability, lasers score over TURP in several ways. Their use is associated with less blood loss, shorter catheter time and decreased hospital stay. The fluid absorption during laser prostatectomy is negligible and thus makes it safer for use...
Source: Indian Journal of Urology - October 1, 2009 Category: Urology & Nephrology Authors: Varshney Anil, Agarwal Anshuman Source Type: journals

Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing worldEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gupta Narmada P, Anand AjayIndian Journal of Urology 2009 25(3):413-414Lasers have been given much hype as regards their use in surgical management of benign prostatic hyperplasia (BPH). Transurethral resection of prostate (TURP), especially with its modifications still remains the gold standard treatment for BPH, owing to its efficacy and proven advantages over laser prostatectomy. Cost, unproven long-term durability, steep learning curve, and no advantages of laser prostatectomy over TURP and its modifications, make lasers superfluous in the surgical management of BPH in developing countries. (Source: Indian Journal of Urology)
Source: Indian Journal of Urology - October 1, 2009 Category: Urology & Nephrology Authors: Gupta Narmada P, Anand Ajay Source Type: journals

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Agrawal S K, Agarwal M M, Singh S KIndian Journal of Urology 2009 25(3):421-423 (Source: Indian Journal of Urology)
Source: Indian Journal of Urology - October 1, 2009 Category: Urology & Nephrology Authors: Agrawal S K, Agarwal M M, Singh S K Source Type: journals

Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, we detected mRNA for LHRH-R-I in human BPH specimens. Our results suggest that LHRH-R-I gene may have more than two splice variants or uncharacterised transcript forms of LHRH-R-I. Our findings support the merit of further investigation of the expression of LHRH-R-I and its transcript forms in human BPH. PMID: 19787259 [PubMed - in process] (Source: International Journal of Oncology)
Source: International Journal of Oncology - October 1, 2009 Category: Cancer & Oncology Authors: Rózsa B, Juhász A, Treszl A, Tóth G, Flaskó T, Dezsö B, Block NL, Schally AV, Halmos G Tags: Int J Oncol Source Type: journals

Editorial CommentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Histotripsy is a method of ultrasound therapy that uses intense bursts of ultrasound to destroy tissue by cavitation rather than thermal mechanisms. The aim of this study is to develop histotripsy as a noninvasive (potentially office based) therapy for the treatment of benign prostatic hyperplasia (BPH) with equivalent efficacy to transurethral resection of the prostate and a more favorable side effect profile. (Source: Urology)
Source: Urology - September 30, 2009 Category: Urology & Nephrology Authors: James C. Ulchaker Tags: Technology and Engineering Source Type: journals

Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based CohortEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms, indicating higher levels of C-reactive protein. American Journal of Epidemiology (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 30, 2009 Category: Urology & Nephrology Tags: Internal Medicine Source Type: info

Burden of male stress urinary incontinence: A survey among urologists in JapanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This survey confirms that a significant number of men suffer from moderate to severe SUI, with the majority of cases being post-prostatectomy incontinence. The Japanese urological community needs to provide appropriate treatment for these patients. (Source: International Journal of Urology)
Source: International Journal of Urology - September 29, 2009 Category: Urology & Nephrology Authors: Yoichi Arai, Yasuhiro Kaiho, Mineo Takei, Katsuya Nonomura, Shiro Baba, Tomonori Habuchi, Tadashi Matsuda, Satoru Takahashi, Mikio Igawa, Haruo Nakagawa Source Type: journals

Effect of the dual 5α-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To investigate the effects of dutasteride on serum testosterone level and body mass index (BMI) in men who received medical therapy for benign prostatic hyperplasia (BPH). In all, 120 patients with BPH were randomized to three treatment groups: tamsulosin 0.2 mg/day ([alpha]-blocker group), dutasteride 0.5 mg/day (dutasteride group), or tamsulosin 0.2 mg plus dutasteride 0.5 mg/day (combination group) for 1 year. For all patients the BMI and serum testosterone levels were checked at baseline and after 1 year of treatment. Among the evaluable 107 patients, the dutasteride (33) and combination groups (37) had significantly g...
Source: BJU International - September 28, 2009 Category: Urology & Nephrology Authors: Sung Kyu Hong, Gyeong Eun Min, Seung Bum Ha, Seung Hwan Doo, Min Yong Kang, Hong Joo Park, Cheol Yong Yoon, Seong Jin Jeong, Seok-Soo Byun, Sang Eun Lee Source Type: journals

Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Obesity, dyslipidemia, Hyperinsulinemia, and insulin resistance (IR) are key features of metabolic syndrome and are considered as risk factors for benign prostatic hyperplasia (BPH) as well as type 2 diabetes. The present study was aimed to determine whether or not IR associated hyperinsulinemia contributes to the BPH.Sprague-Dawley rats (9 weeks) were used in the study. Rats were kept on high fat diet (HFD) for the induction of hyperinsulinemia while hypoinsulinemia was induced by streptozotocin. Effect of HFD feeding on the testosterone-induced prostatic growth was evaluated. Pioglitazone (PG, 20 mg/kg) was used for the ...
Source: The Prostate - September 28, 2009 Category: Urology & Nephrology Authors: A. Vikram, G. B. Jena, P. Ramarao Source Type: journals

Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary TractEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. The highest expression and biological activity of PDE5 was found in bladder. However, a consistent PDE5 expression and activity was also found in prostatic urethra. In contrast, the prostate gland showed the lowest PDE5 abundance and cultures derived from this tissue were less sensitive to vardenafil. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, and Maggi M. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)
Source: The Journal of Sexual Medicine - September 28, 2009 Category: Sexual Medicine Authors: Benedetta Fibbi, Annamaria Morelli, Linda Vignozzi, Sandra Filippi, Aravinda Chavalmane, Giulia De Vita, Mirca Marini, Mauro Gacci, Gabriella Barbara Vannelli, Peter Sandner, Mario Maggi Source Type: journals

Translocator Protein Blockade Reduces Prostate Tumor Growth.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: These data suggest that blocking TSPO function in tumor cells induces cell death and denotes a survival role for TSPO in prostate cancer and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics. (Clin Cancer Res 2009;15(19):6177-84). PMID: 19789311 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - September 28, 2009 Category: Cancer & Oncology Authors: Fafalios A, Akhavan A, Parwani AV, Bies RR, McHugh KJ, Pflug BR Tags: Clin Cancer Res Source Type: journals